ArriVent BioPharma Balance Sheet
NASDAQ: AVBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ArriVent BioPharma financial position
At the end of fiscal 2025, ArriVent BioPharma reported total assets of $333.2 million, up 21.2% from a year earlier against total liabilities of $25.9 million. Shareholders' equity stood at $307.2 million, or 92.2% of assets. The company held $45.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 12.83, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
ArriVent BioPharma balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Cash & Equivalents | 45.54M | 74.29M | 150.39M |
| Short-Term Investments | 267.28M | 144.57M | — |
| Total Current Assets | 332.90M | 226.98M | 159.97M |
| Long-Term Investments | — | 47.68M | — |
| Total Assets | 333.17M | 274.94M | 163.10M |
| Accounts Payable | 5.93M | 3.78M | 4.53M |
| Total Current Liabilities | 25.95M | 17.27M | 11.62M |
| Total Liabilities | 25.95M | 17.29M | 11.80M |
| Shareholders' Equity | 307.22M | 257.65M | -153.19M |
| Retained Earnings | -404.64M | -238.33M | -157.84M |
| Net Cash (Debt) | 312.82M | 218.86M | 150.39M |
| Shares Outstanding | 42.45M | 33.71M | 2.75M |
This table shows 3 annual periods of ArriVent BioPharma's balance sheet, from FY 2025 back to FY 2023, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow AVBP's reporting calendar. What is a balance sheet?